Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected subjects 18 years of age or older~* Receiving HAART for at least two years~* At least a viral load determination per year since HAART initiation, all undetectable~* Patient's status is Immunological Non Responder (InR), that is, his or her viral load is reduced, but CD4+ cell count has not raised accordingly~* Current viral load: undetectable~* Patient agrees and signs informed consent~Exclusion Criteria:~* Concomitant active infectious or neoplastic disease~* History of new AIDS-defining events during HAART~* Pregnancy or breast-feeding~* Patients who have been subjects of an investigational agent, chemotherapy or radiotherapy within the previous 28 days~* Subjects requiring treatment for Tuberculosis~* Subjects unable to follow, or comply with the protocol interventions~* Subjects receiving immunosuppressive treatment, including corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).